Skip to main content
Erschienen in: Critical Care 1/2019

Open Access 01.12.2019 | Letter

How I manage ICP-CPP: a visual, yet individualized approach

verfasst von: William D. Freeman

Erschienen in: Critical Care | Ausgabe 1/2019

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
This comment refers to the article available at https://​doi.​org/​10.​1186/​s13054-019-2529-z.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
I read with great interest Drs. Robba and Citerio’s [1] approach to intracranial pressure (ICP)-cerebral perfusion pressure (CPP) management, and it is to be commended. My approach over the years has evolved to teach a visual pyramidal approach to our nurses, residents, fellows, and now our advanced practice providers and neurosurgeons. Rather than use the Tier 0, 1, 2, 3 system as proposed by the Neurocritical Care Society in Emergency Neurologic Life Support, I often simply provide this Fig. 1 to our teams to show the foundation is laid with basics of CPP (mean arterial pressure-ICP) management. This visual diagram shows that to measure CPP, an ICP monitor and basic interventions like head/neck positioning are needed. The diagram also demonstrates the importance of emphasizing the ICP-CPP zero at the tragus for standardization [2, 3]. These fundamentals cannot be overstated, especially with nurses eager to re-emphasize at bedside the goals of care of the patient. Further, beyond basic CPP management, osmotherapy comes into play, which once exhausted, moves up the pyramid to escalation therapies of refractory ICP, including barbiturates or hypothermia, and ultimately to neurosurgical decompression (“top of the pyramid” literally and figuratively). We find this Fig. 1 useful for discussion, and even management with our fellows, as well as for long-standing issues about use of mannitol versus say hypertonic saline in osmotherapy selection, etc. We find that there is an insatiable academic thirst for knowledge around this topic each year among all team members and hope this Fig. 1 provides food for thought for similar teams at other centers [4].

Acknowledgements

None.
NA.
NA.

Competing interests

The author declares that he has no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Robba C, Citerio G. How I manage intracranial hypertension. Crit Care. 2019;23:243.CrossRef Robba C, Citerio G. How I manage intracranial hypertension. Crit Care. 2019;23:243.CrossRef
2.
Zurück zum Zitat Freeman WD. Management of Intracranial Pressure. Continuum (Minneap Minn). 2015;21:1299–323. Freeman WD. Management of Intracranial Pressure. Continuum (Minneap Minn). 2015;21:1299–323.
3.
Zurück zum Zitat Freeman WD. Cerebral perfusion pressure versus intracranial pressure-driven therapy on outcomes. Crit Care Med. 2015;43:e29.CrossRef Freeman WD. Cerebral perfusion pressure versus intracranial pressure-driven therapy on outcomes. Crit Care Med. 2015;43:e29.CrossRef
4.
Zurück zum Zitat Lewandowski-Belfer JJ, Patel AV, Darracott RM, Jackson DA, Nordeen JD, Freeman WD. Safety and efficacy of repeated doses of 14.6 or 23.4 % hypertonic saline for refractory intracranial hypertension. Neurocrit Care. 2014;20:436–42.CrossRef Lewandowski-Belfer JJ, Patel AV, Darracott RM, Jackson DA, Nordeen JD, Freeman WD. Safety and efficacy of repeated doses of 14.6 or 23.4 % hypertonic saline for refractory intracranial hypertension. Neurocrit Care. 2014;20:436–42.CrossRef
Metadaten
Titel
How I manage ICP-CPP: a visual, yet individualized approach
verfasst von
William D. Freeman
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2019
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2565-8

Weitere Artikel der Ausgabe 1/2019

Critical Care 1/2019 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.